Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: phbolton who wrote (236)	1/24/2000 2:40:00 PM
From: Thomas M.	Read Replies (1) \| Respond to of 523

You mean an Internet strategy is not critical to a biotech company's success? <g> I just said to a friend, that if NRGN is moving, the biotech rally must be near an end. Tom

To: phbolton who wrote (236)	1/25/2000 12:51:00 PM
From: Jim Oravetz	Respond to of 523

Neurogen Launches New Website for AIDD(TM) (Accelerated Intelligent Drug Discovery) System AIDD Allows Companies to Take Advantage of Explosion of New Drug Targets BRANFORD, Conn., Jan. 24 /PRNewswire/ -- Neurogen Corporation (Nasdaq: NRGN), a leading drug discovery and development company, today launched a new website, located at aidd.com, to communicate the benefits of the company's highly efficient drug discovery technology platform. AIDD.com supports the company's marketing efforts for its AIDD(TM) (Accelerated Intelligent Drug Discovery) program and includes a case study, "AIDD in Action," which demonstrates AIDD's discovery and optimization capabilities. Neurogen licenses AIDD to pharmaceutical and biotechnology companies to enhance their drug discovery capabilities and to expedite their exploitation of the new drug targets becoming available to the industry. Jim